Company: STAA
Filing Date: 2025-09-16
Form Type: DEFM14A
Source: 0001193125-25-204396
Chunk: 38

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFM14A
Chunk 38
---
 Board’s recommendations on the Merger Proposal and Compensation Proposal presented in this proxy statement. If STAAR’s largest stockholders do not
vote their shares in support of the adoption of the Merger Agreement, STAAR’s ability to satisfy this closing condition would be materially adversely affected. The proxy contest resulting from the Broadwood Group filing will cause STAAR
stockholders to incur additional solicitation and other costs, and may impair STAAR’s ability to obtain the votes required to approve the Merger Proposal and Compensation Proposal.

In addition, the consummation of the Merger is subject to the expiration or termination of the applicable waiting period (and any extension
thereof) under the HSR Act (which waiting period will expire on September 29, 2025 at 11:59 p.m., Eastern Time, unless otherwise earlier terminated or extended), as well as of any agreement not to close embodied in a “timing
agreement” between the parties and a governmental body, and the receipt of regulatory approvals in other jurisdictions, including China and Japan among others. The relevant governmental entities may impose requirements, limitations or costs or
place restrictions on the conduct of STAAR’s or Alcon’s business following the Merger as a condition to approval or not grant approval at all.

Other conditions that must be satisfied or waived before one or more of the parties will be obligated to consummate the Merger are
(1) the accuracy of the other party’s representations and warranties, subject to certain materiality standards set forth in the Merger Agreement; (2) compliance by the other party in all material respects with such other
party’s obligations and covenants under the Merger Agreement; (3) the absence of any law or order prohibiting consummation of the Merger or that that makes illegal the consummation of the Merger in specified jurisdictions in which STAAR,
Alcon or their respective subsidiaries have business operations; and (4) in the case of Alcon’s and Merger Sub’s obligation to consummate the Merger, the absence of a Material Adverse Effect (as defined in “The Merger Agreement—Representations and Warranties”) on STAAR since the date of the Merger Agreement that is continuing.

STAAR can
provide no assurance that the closing conditions will be fulfilled (or waived, if applicable) in a timely manner or at all, and, if all closing conditions are timely fulfilled (or waived, if applicable), STAAR can provide no assurance as to the
terms, conditions